anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an oxindole spiroallyl substituted chroman skeleton and a synthesis method and application thereof. The invention provides an oxindole spiroallyl substituted chroman structure. The invention provides a synthesis method thereof, which comprises the following steps: the quaternary synthon containing the oxindole skeleton and (E) -1,4-dibromo-2-butene are uniformly mixed in a solvent and react at 50-90 ℃ under an alkaline condition to prepare the oxindole spiroallyl substituted chroman compound. The invention provides a pharmaceutical composition. The invention also provides the application of the oxindole spiroallyl substituted chroman skeleton in preparing medicaments for treating cancers and the like. The method for efficiently synthesizing the oxindole spiroallyl substituted chroman compounds realizes efficient construction of the oxindole spiroallyl substituted chroman skeleton through the (E) -1,4-dibromo-2-butene participating in the [4+2] cyclization reaction.
After completion of the PK study period, subjects will enter a 90-day on-demand treatment period and will be randomized into 3 groups (Group 1: 90 µg/kg, Group 2: 180 µg/kg, and Group 3: 270 µg/kg) at a ratio of 1:1:1. During on-demand treatment, subjects are treated on-demand with SS109 at the time of a new hemorrhage event and their efficacy is observed.
Participants assigned to this group will complete 4 sessions of communication and social support effectiveness training. One follow up call will be completed one month after the last session has been competed.
Multiple sclerosis (MS) is a demyelinating neurological disorder with a highly heterogeneous clinical presentation and course of progression. Disease-modifying therapies are the only available treatment, as there is no known cure for the disease. Careful selection of suitable therapies is necessary, as they can be accompanied by serious risks and adverse effects such as infection. Magnetic resonance imaging (MRI) plays a central role in the diagnosis and management of MS, though MRI lesions have displayed only moderate associations with MS clinical outcomes, known as the clinico-radiological paradox. With the advent of machine learning (ML) in healthcare, the predictive power of MRI can be improved by leveraging both traditional and advanced ML algorithms capable of analyzing increasingly complex patterns within neuroimaging data. The purpose of this review was to examine the application of MRI-based ML for prediction of MS disease progression. Studies were divided into five main categories: predicting the conversion of clinically isolated syndrome to MS, cognitive outcome, EDSS-related disability, motor disability and disease activity. The performance of ML models is discussed along with highlighting the influential MRI-derived biomarkers. Overall, MRI-based ML presents a promising avenue for MS prognosis. However, integration of imaging biomarkers with other multimodal patient data shows great potential for advancing personalized healthcare approaches in MS.
BACKGROUND: The Leicester Cough Questionnaire (LCQ) is a validated tool for assessing cough that has three domains (physical, psychological, and social), with eight, seven, and four items, respectively. However, the assigned domain may not accurately reflect the characteristics of an item. This study aimed to reclassify the items in the Korean version of the LCQ (K-LCQ) to improve the coherence in each domain.
METHODS: Data of patients with chronic cough from 16 centers who completed the K-LCQ were retrospectively analyzed. Spearman's rank correlation analysis was used to assess the correlations between items and their domains. Principal component analysis was performed to recategorize the K-LCQ items.
RESULTS: The correlation analysis of the data from 255 patients demonstrated that certain items such as tiredness, embarrassment, and interference with daily work or overall life enjoyment showed strong or very strong correlations with all three domains. Cough bout frequency showed the weakest correlation with the physical domain, despite being included in that domain, and had stronger correlations with the psychological and social domain. The principal component analysis led to the reclassification of six items: one from the physical to psychological, two from the social to psychological, and three from the psychological to social domain. The within-domain correlation coherence was higher in the new classification than in the original. Validation using an independent cohort of 203 patients yielded similar results.
CONCLUSIONS: The new classification of the K-LCQ items showed improved within-domain correlation coherence.
The present invention relates to a novel virus, said virus belonging to the HIV-2 family of viruses. In particular, the invention relates to a retrovirus characterized by being antigenically more similar to, but genetically distinct from, HIV-2/ROD and SIVMAC than to HIV-1. More particularly, the present invention relates to the isolation and cultivation of HIV-2/ST thereby providing a source of said virus and its derivatives including virus-derived antigens and derivatives and parts thereof, useful in the development of diagnostic assays for said virus or other related viruses belonging to the HIV-2 family. Furthermore, the present invention is also directed to recombinant DNA molecules containing the entire HIV-2/ST provirus thereby providing a source of recombinant viral components useful in the development of said diagnostic assays for HIV-2 viruses. The present invention is also directed to antibodies specific to viral components and to different antibodies specific to the first antibodies, said antibodies are also useful in the development of diagnostic assays for HIV-2 viruses. The present invention also contemplates a method of the isolation of HIV-2/ST-type viruses.
BACKGROUND: Sarcopenic obesity (SO) is a clinical disorder characterized by increased adiposity and decreased muscle mass and function, commonly observed in older adults. However, most of the studies that investigated SO prevalence rates were not based on current standardized diagnostic methods. Thus, this study aims to estimate the prevalence rates of SO and their level of agreement using different instruments proposed by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) Consensus, in a sample of hospitalized older adults with severe obesity.
METHODS: A cross-sectional study with 90 older adults (≥ 60 years) with severe obesity (body mass index ≥ 35 kg/m/²) seeking an in-hospital multidisciplinary body weight reduction program. Skeletal muscle function was assessed using the five-repetition Sit-Stand test (5-SSt) and Handgrip Strength (HGS). Body composition was evaluated by high percentages of fat mass (FM), low appendicular lean mass (ALM/W), and skeletal muscle mass (SMM/W), adjusted to body weight. The stage of SO was assessed on the presence of at least one comorbidity and specific cut-offs were adopted for each step. All analyses were performed according to gender and age range.
RESULTS: The prevalence rates of SO in the total sample were 23.3%, 25.5%, 31.1%, and 40.0% considering altered values of 5-SSt+FM+ALM/W, HGS+FM+ALM/W, 5-SSt+FMSSM/W, and HGS+FM+SSM/W, respectively. Higher prevalence rates were observed among female and old elderly subgroups, regardless of the diagnostic combination. There were weak agreements between the muscle function tests (5-SSt versus HGS) using both muscle mass indexes in the total sample and all subgroups. Moderate agreements were observed between muscle mass indexes (SMM/W versus ALM/W) in the total sample, male and younger older adults (using 5-SSt), and strong agreements for men and younger older adults (using HGS).
CONCLUSION: The discrepancies observed between the prevalence rates and their levels of agreement reinforce the need for new studies in similar populations aiming for better standardization of SO assessment.
Streptococcus pneumoniae (SP) is the major cause of bacterial infection in HIV-infected patients. The 23-valent pneumococcal polysaccharide (PPV) is poorly immunogenic in patients with CD4 below 500 cells/mm3. The purpose of this multicentric national study is to evaluate whether a prime with a 7-valent pneumococcal conjugate vaccine (PCV), able to induce immunological memory, would improve immunogenicity against SP polysaccharides. 212 HIV-1 infected patients, with a CD4 count between 200 and 500/mm3, will be randomly assigned to one of two vaccine groups: PCV at Week 0 followed by PPV at Week 4 or PPV alone at Week 4. Evaluation will be done at week 8. The primary endpoint is the proportion of patients who had antibody responses against 7 pneumococcal polysaccharides at Week 8. Secondary endpoints include the persistence of antibody responses at Weeks 24 and 96, vaccines safety and occurrence of pneumococcal disease over time.
The invention relates to a method for producing a polyvalent vaccine of an influenza hemagglutinin. The invention provides a method for preparing a recombined influenza vaccine by using the technology of DNA. The produced vaccine is polyvalent, preferably to be trivalent and is based on the influenza vaccine of a recombined hemagglutinin antigen compound cloning from an influenza virus with an epidemic potential. The recombined hemagglutinin antigen is whole-length glycosidoprotein which is not cut (HAO), generated from a rhabdovirus expression vector for culturing an insect cell and purified under a non-denatured condition. In the preferable implementing scheme, the cloned HA gene is decorated by cutting a natural hydrophobic signal peptide sequence and using a novel rhabdovirus of chitinase signal peptide to replace. The invention also discloses a common method used for effectively distilling and purifying the recombined HA protein generated from the insect cell from the rHA protein purified from the influenza viruses of A subtype and B type.
PROBLEM TO BE SOLVED: To obtain the subject agent by including a complex ingredient contained in a culture mycelium or a culture filtrate of Agaricus blazei Murr. as an active ingredient therein. SOLUTION: This agent contains a water-soluble complex ingredient contained in a culture mycelium or a culture filtrate of Kawariharatake (Agaricus blazei Murr.) which is mushroom of the genus Agaricus, commonly named Himematsutake. The complex ingredient contained in the culture mycelium obtained by carrying out the extraction treatment of the culture mycelium of the Himematsutake with hot water, then precipitating the extract with an alcohol and purifying the precipitated substance by chromatographic fractionation and/or separation with a membrane. The complex ingredient contained in the culture filtrate is prepared by performing the precipitating treatment of the culture filtrate of the Himamatsutake with the alcohol and then purifying the resultant precipitated substance by the chromatographic fractionation and/or separation with the membrane.  The water-soluble complex ingredient has actions on remarkable reduction in AIDS symptoms by orally administering the ingredient to patients suffering from the AIDS and has no problem in acute and subacute toxicities.
Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
After administering a dose of the therapeutic agent, residual amounts of the agent and/or other contaminants may remain on the outside surface of the dispensing tip. Disclosed herein is an apparatus for dispensing a sterile, non-preserved therapeutic liquid. The apparatus comprises a container, a vented cap, a second cap and a tamper evident seal. The container is configured to hold the sterile, non-preserved therapeutic liquid and has a dispensing tip configured to dispense a dose of the therapeutic liquid. The vented cap is configured to fit over at least a portion of the container including the dispensing tip and has one or more vents that allow air to pass into and out of a cavity defined between the vented cap and the dispensing tip. The second cap configured is to fit over at least a portion of the vented cap. The tamper evident seal coupled to the second cap and one or both of the container and the vented cap.
Dicyclomine relieves smooth muscle spasm of the gastrointestinal tract. Animal studies indicate that this action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine (in vitro, guinea pig ileum); and (2) a direct effect upon smooth muscle (musculotropic) as evidenced by dicyclomine's antagonism of bradykinin- and histamine-induced spasms of the isolated guinea pig ileum. Atropine did not affect responses to these two agonists. In vivo studies in cats and dogs showed dicyclomine to be equally potent against acetylcholine (ACh)- or barium chloride (BaCl2)-induced intestinal spasm while atropine was at least 200 times more potent against effects of ACh than BaCl2. Tests for mydriatic effects in mice showed that dicyclomine was approximately 1/500 as potent as atropine; antisialagogue tests in rabbits showed dicyclomine to be 1/300 as potent as atropine.

In man, dicyclomine is rapidly absorbed after oral administration, reaching peak values within 60-90 minutes. The principal route of elimination is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%). Mean half-life of plasma elimination in one study was determined to be approximately 1.8 hours when plasma concentrations were measured for 9 hours after a single dose. In subsequent studies, plasma concentrations were followed for up to 24 hours after a single dose, showing a secondary phase of elimination with a somewhat longer half-life. Mean volume of distribution for a 20 mg oral dose is approximately 3.65 L/kg suggesting extensive distribution in tissues.

In controlled clinical trials involving over 100 patients who received drug, 82% of patients treated for functional bowel/irritable bowel syndrome with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg q.i.d.) demonstrated a favorable clinical response compared with 55% treated with placebo (p<.05). In these trials most of the side effects were typically anticholinergic in nature (see table) and were reported by 61% of the patients.

Nine percent (9%) of patients were discontinued from the drug because of one or more of these side effects (compared with 2% in the placebo group). In 41% of the patients with side effects, side effects disappeared or were tolerated at the 160 mg daily dose without reduction. A dose reduction from 160 mg daily to an average daily dose of 90 mg was required in 46% of the patients with side effects who then continued to experience a favorable clinical response; their side effects either disappeared or were tolerated. (See ADVERSE REACTIONS.)
The Care Coordination group applies the current methods of the federally qualified health center (FHQC) Patient Centered Medical Home initiative. Participants assigned to the care coordination group will continue with their regular medical visits with their primary care provider. In addition, they will receive care coordination and brief targeted health education provided by a specially trained medical assistant/care coordinator. This will involve 1 or more brief sessions with a care coordinator to provide health education, assist with appointments and referrals, and review medications. The care coordinator will work closely with their primary care provider. The care coordinator will also assist with referrals to behavioral health that may be initiated by the primary care provider.
Primary prophylactic brimonidine tartrate ophthalmic solution eye drops 3 times daily (TID) on Days 1 to 8 of each cycle (vasoconstricting drops should be started on the day of first infusion and should begin before the first infusion on Cycle 1 Day 1); Lubricating eye drops QID throughout the entire cycle (doses should follow brimonidine dosing, when given, by approximately 15 minutes); MIRV 6 mg/kg AIBW Q3W on Day 1 of each cycle. Each cycle length = 21 days.
Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.6)]. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. 

Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.
FIELD: veterinary science, virology. SUBSTANCE: blood is treated with strong organic acid solution, potassium permanganate is added to protein-free filtrate up to concentration 0.06-0.08% and mixture is distilled in capacity with Nash reagent for formaldehyde assay. Encephalopathy is diagnosed at amount of formaldehyde 0.4-18 mM. Method is used for early detection of viral diseases in animals. EFFECT: improved method of diagnosis. 1 dwg, 2 tbl
Group epidural, 0.5% buvasin® will be applied epidural space in the lateral position after monitoring. The patient will be placed in the supine position and surgery will begin when the T5 spinal level is achieved. Pregnant heart rate, blood pressure and saturation values will be recorded at intervals and iv ephedrine will be administered when there is a 25% or more drop in blood pressure. When there is a 25% or more decrease in heart rate, iv atropine will be administered. A NIRS probe (infant,saturation sensor, Invos , Tullamore, Ireland) and pulse will be attached to the newborn by another anesthetist and the measurements will be recorded. Blood pressure will be taken from the umbilical vein. APGAR(activity,pulse,grimace,appearance,respiration), heart rate, SpO2 and umbilical vein saturation values of the newborn will be recorded. NIRS and spO2 values of the newborn will be checked intermittently.
High risk of injuries and painful symptoms in athletes and dancers (especially classical ballerinas) may lead to reduced functional performance. The use of photobiomodulation may improve functional performance in ballerinas that are affected by foot pain. An aluminum gallium arsenide (AlGaAs) diode laser device was uded. Infrared laser (808 nm) was applied on ballerina's feet twice a week during three months. Thermography, algometry and unipodal static standing balance test were performed. There were pain relief and improvement of functional performance in ballerinas.
The invention discloses a nylon/silicon dioxide composite microsphere and a preparation method and application thereof. The composite microspheres are spherical and/or nearly spherical particles with the particle size of 0.5-300 mu m, and consist of a porous nylon microsphere matrix and silicon dioxide uniformly dispersed in pores and/or surfaces of the porous nylon microspheres. Wherein the content of the nylon microspheres containing holes is 10-99.9 wt%, and the content of the silicon dioxide is 0.1-90 wt%. The composite microsphere is obtained by carrying out in-situ hydrolysis on silicon dioxide in a porous nylon microsphere dispersion liquid. The addition of the silicon dioxide can effectively reduce the water absorption of the porous nylon composite microspheres and improve the thermal stability, crystallization property and mechanical strength. The composite microsphere can be used as a consumable material of an SLS selective laser sintering technology, and the application of the SLS technology in the fields of aviation, automobiles, medical instruments, electronic instruments, mechanical dies, artworks and the like is widened.
To our knowledge, calibration curves or other validations for thousands of SomaScan aptamers are not publicly available. Moreover, the abundance of urine proteins obtained from these assays is not routinely validated with orthogonal methods (OMs). We report an in-depth comparison of SomaScan readout for 23 proteins in urine samples from patients with diabetic kidney disease (n = 118) vs OMs, including liquid chromatography-targeted mass spectrometry (LC-MS), ELISA, and nephelometry. Pearson correlation between urine abundance of the 23 proteins from SomaScan 3.2 vs OMs ranged from -0.58 to 0.86, with a median (interquartile ratio, [IQR]) of 0.49 (0.18, 0.53). In multivariable linear regression, the SomaScan readout for 6 of the 23 examined proteins (26%) was most strongly associated with the OM-derived abundance of the same (target) protein. For 3 of 23 (13%), the SomaScan and OM-derived abundance of each protein were significantly associated, but the SomaScan readout was more strongly associated with OM-derived abundance of one or more "off-target" proteins. For the remaining 14 proteins (61%), the SomaScan readouts were not significantly associated with the OM-derived abundance of the targeted proteins. In 6 of the latest group, the SomaScan readout was not associated with urine abundance of any of the 23 quantified proteins. To sum, over half of the SomaScan results could not be confirmed by independent orthogonal methods.
Sleep disorders are prevalent and often neglected among breast cancer patients. This study aimed to identify the association among perceived stress, loneliness, resilience and sleep disorders and to further explore whether resilience could be a moderator in the association between them and sleep disorders. A cross-sectional study was conducted by 492 female breast cancer patients. Patients were asked in response to the questionnaires including the Pittsburgh Sleep Quality Index, Perceived Stress Scale-10, the Three-Item Loneliness Scale and Resilience Scale-14. The association among perceived stress, loneliness, resilience and perceived stress/loneliness × resilience interaction with sleep disorders were examined by hierarchical multiple regression analysis. The interaction was visualized by using simple slope analysis. 36.58% of the female breast cancer patients reported sleep disorders in our study. Perceived stress and loneliness were related to sleep disorders. Resilience could moderate the relationship between them and sleep disorders. When resilience was higher, perceived stress and loneliness had a weaker impact on sleep disorders. Medical staff should systematically evaluate the internal environmental factors related to patients' sleep quality and help patients relieve their emotional distress caused by the disease through positive psychological guidance.
Electrodes will be placed in the same 4x1 ring configuration over the frontal region as the active left frontal condition to ensure a useful control condition. Stimulation will consist of a 30-second ramp up period until reaching 2 mA, followed immediately by a 30-second ramp down, and off for 29 minutes. The same ramp up and down process will be repeated in the final minute of the session to help preserve masking of conditions. Sham stimulation will be applied back-to-back over three consecutive days.